Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shorter h. pylori treatment shows promise in new trial

NCT ID NCT05371249

Disease control Sponsor: Fu Jen Catholic University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This trial tests whether a 7-day course of vonoprazan combined with high-dose amoxicillin and clarithromycin can eradicate H. pylori infection as effectively as the current 14-day extended sequential therapy. About 628 adults with H. pylori infection will be randomly assigned to one of the two treatments. The main goal is to compare eradication rates, with secondary focus on side effects and how well patients follow the regimen.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
vonoprazan, amoxicillin, and clarithromycin combination
What this could lead to
If successful, this could offer a shorter, simpler treatment option for H. pylori infection with similar or better eradication rates.
What could go wrong
This is a phase 4 trial comparing existing treatments, so the new regimen may not prove superior and could have side effects like any antibiotic therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

628 people

The number who actually took part.

Started

Dec 2021

Finished

Feb 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with H.pylori infection who was over 20 years old and agree to participate in the trial will be recruited. Exclusion Criteria: * Who had received helicobacter pylori eradication before * Who are known to be allergic to any drug used in this trial * Pregnant women * Who are refuse to participate in the trial for any reason

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Helicobacter pylori are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Helicobacter pylori infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Helicobacter pylori

Contacts and locations

Locations

  • Fu Jen Catholic University Hospital

    New Taipei City, 243, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.